Goldman Sachs Group Inc Landos Biopharma, Inc. Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.67 - $1.26 $19,904 - $37,432	-29,708 Reduced 69.41%	13,092 $9,000
Q3 2022 Nov 10, 2022	SELL	$0.67 - $1.26 $19,904 - $37,432	-29,708 Reduced 69.41%	13,092 $0
Q2 2022 May 14, 2024	BUY	$0.6 - $1.5 $25,680 - $64,200	42,800 New	42,800 $31,000
Q2 2022 Aug 15, 2022	BUY	$0.6 - $1.5 $13,957 - $34,894	23,263 Added 119.07%	42,800 $31,000
Q1 2022 May 16, 2022	BUY	$1.44 - $5.22 $2,835 - $10,278	1,969 Added 11.21%	19,537 $29,000
Q4 2021 Feb 14, 2022	BUY	$4.7 - $15.0 $82,569 - $263,520	17,568 New	17,568 $84,000

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.